Selected Quarterly Financial Information

12 Months Ended

Dec. 31, 2012

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Financial Information

SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)

(in thousands, except per share data)

	First		Second		Third			Fourth
	Quarter		Quarter		Quarter			Quarter
REVENUE:
2012	$	32,301	$	33,188	$	33,429		$	32,800
2011		30,196		29,379		29,654			30,397
2010		29,717		29,263		28,443			29,222
GROSS MARGIN:
2012	$	21,292	$	21,371	$	21,310		$	21,045
2011		18,504		19,053		18,912			19,375
2010		17,792		17,769		15,222	*		17,585
NET INCOME (LOSS):
2012	$	991	$	3,334	$	1,538		$	2,083
2011		1,666		1,820		2,019			1,866
2010		1,934		2,926		(3,031)	*		2,115
INCOME (LOSS) PER COMMON SHARE—DILUTED:
2012	$	0.04	$	0.12	$	0.06		$	0.07
2011		0.06		0.06		0.07			0.07
2010		0.07		0.10		(0.11)	*		0.08

*The third quarter 2010 gross margin, net loss, and loss per share-diluted includes the unfavorable effect of a $1.6 million write-down of HemoStase inventory as a result of Medafor, Inc.’s termination of the distribution agreement between the parties.  The third quarter 2010 net loss and loss per share-diluted also includes the unfavorable effects of $3.5 million in acquired in-process research and development expense, as a result of the transaction with Starch Medical, Inc., and $3.6 million for the other than temporary impairment of the Company’s investment in Medafor common stock.